An observational study in Neuromuscular Disease Patients and Central Neurological Disease Patients, sponsored by Beth Israel Deaconess Medical Center. Completed at 1 site in United States. Open to participants aged 21 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-16.
Sponsored by Beth Israel Deaconess Medical Center · Observational
Overview of study. This is an observational study that is intended to provide the first in-human data using EIT as a biomarker of muscle health in neuromuscular conditions. We will seek patients with neurological disorders (both neuromuscular and other neurological conditions) as well as healthy subjects for study. EIT measurements will be performed on appendicular muscles (in the upper and lower extremities) depending on the condition, both at rest and with contraction. EIT measurements will be repeated on an intermittent basis to assess repeatability as well disease progression or improvement over time.
History and examination (All participants). After reviewing the purpose and procedures of the study, the subject, or a legally authorized representative (LAR), will be asked to sign the internal review board-approved informed consent form.
Basic medical, social, and family histories will then be obtained and recorded. Previous medical records will be reviewed and the neurological diagnosis confirmed when possible. Information including Body Mass Index (BMI), presence of a gastrostomy, imaging findings, and blood tests will be noted when available. Medications, including drug doses, history of recent medication changes, and duration of treatment) will be reviewed.
Brief general neurological examinations will then be completed.
EIT measurements (All participants).We will be using a SwissTom Pioneer EIT data acquisition system. SwissTom has developed a clinical EIT system which is not FDA-approved, although approved in Europe for lung imaging. It comprises an elastic belt that is connected to a computer via a universal serial bus (USB) or an Ethernet cable. Via multiple surface electrodes on the belt, EIT data is captured and transmitted via the USB or Ethernet cable to the computer. Low resolution, tomography-like impedance images of the muscle are computed and displayed on the computer. The impedance images will be used to evaluate muscle recruitment and other muscle function parameters.
The data acquisition system includes a unit that transmits a small imperceptible electrical current into the chest, via a pair of operator-selected electrodes, while voltage is sensed on all remaining electrodes. The frequency of the transmitted current ranges from 100 Hz to 1 MHz. For frequencies from 100 Hz to 1 kHz, the current amplitude is limited to a maximum of 0.1 mA. From 1 kHz to 100 kHz, the current amplitude is limited to a maximum of 0.1*f mA, where f is the frequency of the current. For frequencies higher than 100 kHz, the current amplitude is limited to a maximum of 10 mA. This meets the safety requirements for applied current as specified in the International Electrotechnical Commission (IEC) 60601-1 safety standard for medical devices.
During data acquisition, the patient may be asked to contract the muscles against resistance of the examiner or against a standard force transducer. The patient may also be asked to contract the muscle while holding a weight in the hand or with a weighted band around the ankle.
EIT measurements may be repeated to assess repeatability within the session.
300 studies on the registry are indexed under Neuromuscular Diseases; 87 are open to participants now.
This study's enrollment of 36 is below the median of 77 across 121 observational studies indexed under Neuromuscular Diseases.
Browse Neuromuscular Diseases studies →Beth Israel Deaconess Medical Center is the lead sponsor of 560 studies on the registry; 80 are open to participants now.
Of its 75 completed or terminated interventional studies of FDA-regulated products, 61 (81%) have results posted.
Counted across the registry records on this site, refreshed daily.
Neuromuscular disease patients (well-defined, localized or generalized neuromuscular condition producing weakness or muscle atrophy, including disuse atrophy) and Central neurological disease patients (well-defined disorder affecting the central nervous system that impacts motor function, including stroke, Parkinson's disease, dystonia, and multiple sclerosis)
Healthy volunteers
Inclusion Criteria:
Exclusion Criteria:
Neuromuscular disease patients:
Inclusion criteria:
Exclusion criteria:
Central neurological disease patients:
Inclusion criteria:
Exclusion criteria:
EIT measurements will be performed on appendicular muscles (in the upper and lower extremities) depending on the condition, both at rest and with contraction. EIT measurements will be repeated on an intermittent basis to assess repeatability as well disease progression or improvement over time
EIT measurements will be performed on appendicular muscles (in the upper and lower extremities) depending on the condition, both at rest and with contraction. EIT measurements will be repeated on an intermittent basis to assess repeatability as well disease progression or improvement over time
To establish normative values for EIT data and reproducibility in adult healthy subjects.
First, we will assess simple percent variability by comparing test-retest measurements and calculating absolute value differences. Secondly, we will perform intraclass correlation analysis of test-retest data. Third, we will perform Bland-Altman analyses with calculation of precision. By performing all three approaches, we will obtain the most complete assessment of the technique's reliability.
Time frame: 1 year
To identify EIT signal data to assist in characterizing muscle as impacted by neuromuscular diseases versus healthy controls versus central neurological conditions.
We will test for over-fitting the data and ensure that the outcomes used are generally applicable. Initial analysis will consist of one-way ANOVA with post-hoc t-tests to confirm basic discrimination followed by ROC analyses. The goal will be to identify the best set of metrics for disease discrimination.
Time frame: 1 year
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beth Israel Deaconess Medical Center